Ascletis Pharma Inc
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory … Read more
Ascletis Pharma Inc - Asset Resilience Ratio
Ascletis Pharma Inc (ASCLF) has an Asset Resilience Ratio of 10.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Ascletis Pharma Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ascletis Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $199.90 Million | 10.01% |
| Total Liquid Assets | $199.90 Million | 10.01% |
Asset Resilience Insights
- Moderate Liquidity: Ascletis Pharma Inc has 10.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Ascletis Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Ascletis Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Ascletis Pharma Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Ascletis Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 50.92% | $1.08 Billion | $2.12 Billion | -28.14pp |
| 2023-12-31 | 79.06% | $1.97 Billion | $2.49 Billion | +0.84pp |
| 2022-12-31 | 78.22% | $2.08 Billion | $2.66 Billion | +78.03pp |
| 2021-12-31 | 0.18% | $5.20 Million | $2.83 Billion | +0.11pp |
| 2020-12-31 | 0.07% | $2.21 Million | $3.07 Billion | -0.07pp |
| 2019-12-31 | 0.14% | $4.79 Million | $3.43 Billion | +0.09pp |
| 2018-12-31 | 0.05% | $1.66 Million | $3.53 Billion | -14.46pp |
| 2017-12-31 | 14.51% | $143.83 Million | $991.25 Million | +13.46pp |
| 2016-12-31 | 1.05% | $5.61 Million | $536.26 Million | -- |